Robert A Yokel

List of Publications by Year
in descending order

162 papers	9,310 citations	34016 52 h-index	42291 92 g-index
169 all docs	169 docs citations	169 times ranked	8630 citing authors

#	Article	IF	Citations
1	Human Health Risk Assessment for Aluminium, Aluminium Oxide, and Aluminium Hydroxide. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2007, 10, 1-269.	2.9	741
2	Increased lever pressing for amphetamine after pimozide in rats: implications for a dopamine theory of reward. Science, 1975, 187, 547-549.	6.0	503
3	Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts. Critical Reviews in Toxicology, 2014, 44, 1-80.	1.9	446
4	Attenuation of intravenous amphetamine reinforcement by central dopamine blockade in rats. Psychopharmacology, 1976, 48, 311-318.	1.5	329
5	Both positive reinforcement and conditioned aversion from amphetamine and from apomorphine in rats. Science, 1976, 191, 1273-1275.	6.0	296
6	Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. Journal of Controlled Release, 2004, 95, 613-626.	4.8	278
7	Aluminium Toxicokinetics: An Updated MiniReview. Basic and Clinical Pharmacology and Toxicology, 2001, 88, 159-167.	0.0	277
8	Manufactured Aluminum Oxide Nanoparticles Decrease Expression of Tight Junction Proteins in Brain Vasculature. Journal of NeuroImmune Pharmacology, 2008, 3, 286-295.	2.1	233
9	Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration. Journal of Alzheimer's Disease, 2006, 10, 223-253.	1.2	231
10	Engineered nanomaterials: exposures, hazards, and risk prevention. Journal of Occupational Medicine and Toxicology, 2011, 6, 7.	0.9	166
11	Drug level of d- and l-amphetamine during intravenous self-administration. Psychopharmacology, 1974, 34, 255-264.	1.5	165
12	Amphetamine-type reinforcement by dopaminergic agonists in the rat. Psychopharmacology, 1978, 58, 289-296.	1.5	165
13	Aluminum chelation principles and recent advances. Coordination Chemistry Reviews, 2002, 228, 97-113.	9.5	157
14	Manganese Distribution Across the Bloodâ€"Brain Barrier. NeuroToxicology, 2003, 24, 3-13.	1.4	154
15	Aluminum bioavailability from basic sodium aluminum phosphate, an approved food additive emulsifying agent, incorporated in cheese. Food and Chemical Toxicology, 2008, 46, 2261-2266.	1.8	146
16	The Speciation of Metals in Mammals Influences Their Toxicokinetics and Toxicodynamics and Therefore Human Health Risk Assessment1. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2006, 9, 63-85.	2.9	115
17	Distribution, Elimination, and Biopersistence to 90 Days of a Systemically Introduced 30 nm Ceria-Engineered Nanomaterial in Rats. Toxicological Sciences, 2012, 127, 256-268.	1.4	114
18	Aluminum Exposure and Metabolism. Critical Reviews in Clinical Laboratory Sciences, 1997, 34, 439-474.	2.7	113

#	Article	IF	Citations
19	Aluminium content of some foods and food products in the USA, with aluminium food additives. Food Additives and Contaminants, 2005, 22, 234-244.	2.0	110
20	Manganese Flux Across the Bloodâ€"Brain Barrier. NeuroMolecular Medicine, 2009, 11, 297-310.	1.8	108
21	The yin: an adverse health perspective of nanoceria: uptake, distribution, accumulation, and mechanisms of its toxicity. Environmental Science: Nano, 2014, 1, 406-428.	2.2	106
22	Brain uptake, retention, and efflux of aluminum and manganese.. Environmental Health Perspectives, 2002, 110, 699-704.	2.8	105
23	Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by aids viruses. Journal of Drug Targeting, 2010, 18, 381-388.	2.1	104
24	Brain Distribution and Toxicological Evaluation of a Systemically Delivered Engineered Nanoscale Ceria. Toxicological Sciences, 2010, 116, 562-576.	1.4	95
25	Manganese Distribution Across the Bloodâ€"Brain Barrier III The Divalent Metal Transporter-1 is not the Major Mechanism Mediating Brain Manganese Uptake. NeuroToxicology, 2004, 25, 451-460.	1.4	94
26	Biodistribution and oxidative stress effects of a systemically-introduced commercial ceria engineered nanomaterial. Nanotoxicology, 2009, 3, 234-248.	1.6	92
27	The distribution of aluminum into and out of the brain. Journal of Inorganic Biochemistry, 1999, 76, 127-132.	1.5	90
28	The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethyl-, 1,2 diethyl-, and 1-[ethan-1â€² ol]-2-methyl-3-hydroxypyridin-4-one in the rat. Toxicology, 1996, 108, 191-199.	2.0	87
29	Biodistribution and biopersistence of ceria engineered nanomaterials: size dependence. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 398-407.	1.7	87
30	Entry, Half-Life, and Desferrioxamine-Accelerated Clearance of Brain Aluminum after a Single 26Al Exposure. Toxicological Sciences, 2001, 64, 77-82.	1.4	81
31	Intravenous Self-Administration: Response Rates, the Effects of Pharmacological Challenges, and Drug Preference. , 1987, , 1-33.		80
32	Manganese distribution across the bloodâ€"brain barrierIV. Evidence for brain influx through store-operated calcium channels. NeuroToxicology, 2005, 26, 297-307.	1.4	78
33	Alteration of hepatic structure and oxidative stress induced by intravenous nanoceria. Toxicology and Applied Pharmacology, 2012, 260, 173-182.	1.3	78
34	RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model. Oncotarget, 2015, 6, 14766-14776.	0.8	78
35	Correlation of R2 with total iron concentration in the brains of rhesus monkeys. Journal of Magnetic Resonance Imaging, 2005, 21, 118-127.	1.9	77
36	Interactions between SIRT1 and AP-1 reveal a mechanistic insight into the growth promoting properties of alumina (Al2O3) nanoparticles in mouse skin epithelial cells. Carcinogenesis, 2008, 29, 1920-1929.	1.3	77

#	Article	IF	Citations
37	Aluminum bioavailability and disposition in adult and immature rabbits. Toxicology and Applied Pharmacology, 1985, 77, 344-352.	1.3	73
38	Aluminum chelation: Chemistry, clinical, and experimental studies and the search for alternatives to desferrioxamine. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1994, 41, 131-174.	1.1	72
39	Aluminum bioavailability from the approved food additive leavening agent acidic sodium aluminum phosphate, incorporated into a baked good, is lower than from water. Toxicology, 2006, 227, 86-93.	2.0	72
40	Aluminum Facilitation of Iron-Mediated Lipid Peroxidation Is Dependent on Substrate, pH, and Aluminum and Iron Concentrations. Archives of Biochemistry and Biophysics, 1996, 327, 222-226.	1.4	71
41	Silver nanoparticles induce tight junction disruption and astrocyte neurotoxicity in a rat blood–brain barrier primary triple coculture model. International Journal of Nanomedicine, 2015, 10, 6105.	3.3	70
42	Intraneuronal aluminum potentiates iron-induced oxidative stress in cultured rat hippocampal neurons. Brain Research, 1996, 743, 271-277.	1.1	69
43	Inâ€…Vivo Processing of Ceria Nanoparticles inside Liver: Impact on Freeâ€Radical Scavenging Activity and Oxidative Stress. ChemPlusChem, 2014, 79, 1083-1088.	1.3	65
44	Manganese Distribution Across the Bloodâ€"Brain Barrier. NeuroToxicology, 2003, 24, 15-22.	1.4	61
45	Toxicity of gestational aluminum exposure to the maternal rabbit and offspring. Toxicology and Applied Pharmacology, 1985, 79, 121-133.	1.3	59
46	Toxicity of aluminum exposure to the neonatal and immature rabbit*1, *2. Fundamental and Applied Toxicology, 1987, 9, 795-806.	1.9	58
47	Biokinetics of nanomaterials: The role of biopersistence. NanoImpact, 2017, 6, 69-80.	2.4	58
48	Aluminum bioavailability from drinking water is very low and is not appreciably influenced by stomach contents or water hardness. Toxicology, 2001, 161, 93-101.	2.0	57
49	The Chemical Species of Aluminum Influences Its Paracellular Flux across and Uptake into Caco-2 Cells, a Model of Gastrointestinal Absorption. Toxicological Sciences, 2005, 87, 15-26.	1.4	56
50	Alternating Magnetic Field-Induced Hyperthermia Increases Iron Oxide Nanoparticle Cell Association/Uptake and Flux in Bloodâ€"Brain Barrier Models. Pharmaceutical Research, 2015, 32, 1615-1625.	1.7	56
51	Aluminum citrate uptake by immortalized brain endothelial cells: implications for its bloodâ€"brain barrier transport. Brain Research, 2002, 930, 101-110.	1.1	55
52	Aluminum bioavailability from tea infusion. Food and Chemical Toxicology, 2008, 46, 3659-3663.	1.8	55
53	Antipyrine as a dialyzable reference to correct differences in efficiency among and within sampling devices during in vivo microdialysis. Journal of Pharmacological and Toxicological Methods, 1992, 27, 135-142.	0.3	54
54	PREVENTION AND TREATMENT OF ALUMINUM TOXICITY INCLUDING CHELATION THERAPY: STATUS AND RESEARCH NEEDS. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1996, 48, 667-684.	1.1	54

#	Article	IF	Citations
55	Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. Toxicology and Applied Pharmacology, 1988, 95, 32-43.	1.3	50
56	Dissimilar Aluminum and Gallium Permeation of the Blood-Brain Barrier Demonstrated by In Vivo Microdialysis. Journal of Neurochemistry, 1992, 58, 903-908.	2.1	49
57	Aluminum distribution into brain and liver of rats and rabbits following intravenous aluminum lactate or citrate: A microdialysis study*1, *2. Toxicology and Applied Pharmacology, 1991, 107, 153-163.	1.3	48
58	An Aluminum-Induced Increase in GFAP Is Attenuated by Some Chelators. Neurotoxicology and Teratology, 1998, 20, 55-60.	1.2	47
59	Concurrent intracranial self-stimulation and amphetamine self-administration in rats. Pharmacology Biochemistry and Behavior, 1977, 7, 459-461.	1.3	46
60	Ceria-engineered nanomaterial distribution in, and clearance from, blood: size matters. Nanomedicine, 2012, 7, 95-110.	1.7	46
61	The neurotoxic potential of engineered nanomaterials. NeuroToxicology, 2012, 33, 902-910.	1.4	45
62	Rat brain pro-oxidant effects of peripherally administered 5nm ceria 30 days after exposure. NeuroToxicology, 2012, 33, 1147-1155.	1.4	44
63	Toxicity of aluminum exposure during lactation to the maternal and suckling rabbit*1. Toxicology and Applied Pharmacology, 1984, 75, 35-43.	1.3	43
64	Aluminum produces age related behavioral toxicity in the rabbit. Neurotoxicology and Teratology, 1989, 11, 237-242.	1.2	41
65	From Dose to Response: In Vivo Nanoparticle Processing and Potential Toxicity. Advances in Experimental Medicine and Biology, 2017, 947, 71-100.	0.8	41
66	The influence of citrate, maltolate and fluoride on the gastrointestinal absorption of aluminum at a drinking water-relevant concentration: A 26Al and 14C study. Journal of Inorganic Biochemistry, 2008, 102, 798-808.	1.5	40
67	Studies of aluminum neurobehavioral toxicity in the intact mammal. Cellular and Molecular Neurobiology, 1994, 14, 791-808.	1.7	39
68	Aluminum citrate is transported from brain into blood via the monocarâ˜ylic acid transporter located at the blood-brain barrier. Toxicology, 1997, 120, 89-97.	2.0	39
69	The Hexadentate Hydroxypyridinonate TRENâ€(Meâ€3,2â€HOPO) is a More Orally Active Iron Chelator Than Its Bidentate Analogue. Journal of Pharmaceutical Sciences, 2000, 89, 545-555.	1.6	39
70	Elevated aluminum persists in serum and tissues of rabbits after a six-hour infusion. Toxicology and Applied Pharmacology, 1989, 99, 133-138.	1.3	38
71	Challenges in characterizing the environmental fate and effects of carbon nanotubes and inorganic nanomaterials in aquatic systems. Environmental Science: Nano, 2018, 5, 48-63.	2.2	37
72	4-trimethylammonium antipyrine: A quaternary ammonium nonradionuclide marker for blood-brain barrier integrity during in vivo microdialysis. Journal of Pharmacological and Toxicological Methods, 1992, 28, 129-135.	0.3	36

#	Article	IF	Citations
73	Abuse and Pulmonary Complications of Injecting Pentazocine and Tripelennamine Tablets. Clinical Toxicology, 1979, 14, 301-306.	0.5	34
74	Evidence for energy-dependent transport of aluminum out of brain extracellular fluid. Toxicology, 1995, 98, 31-39.	2.0	33
75	Aluminum reproductive toxicity: a summary and interpretation of scientific reports. Critical Reviews in Toxicology, 2020, 50, 551-593.	1.9	32
76	Evaluation of 3,4-Hydroxypyridinecarboxylic Acids as Possible Bidentate Chelating Agents for Aluminium(III): Synthesis and Metalâˆ'Ligand Solution Chemistry. European Journal of Inorganic Chemistry, 2002, 2002, 2648-2655.	1.0	31
77	Influence of surface charge on lysozyme adsorption to ceria nanoparticles. Applied Surface Science, 2012, 258, 5332-5341.	3.1	31
78	Block Copolymer Cross-Linked Nanoassemblies Improve Particle Stability and Biocompatibility of Superparamagnetic Iron Oxide Nanoparticles. Pharmaceutical Research, 2013, 30, 552-561.	1.7	31
79	Metalâ€based nanoparticle interactions with the nervous system: the challenge of brain entry and the risk of retention in the organism. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2013, 5, 346-373.	3.3	31
80	Binding, Transcytosis and Biodistribution of Anti-PECAM-1 Iron Oxide Nanoparticles for Brain-Targeted Delivery. PLoS ONE, 2013, 8, e81051.	1.1	31
81	Assessment of potential aluminum chelators in an octanol/aqueous system and in the aluminum-loaded rabbit. Toxicology and Applied Pharmacology, 1987, 91, 281-294.	1.3	29
82	Physiologically based pharmacokinetic modeling of nanoceria systemic distribution in rats suggests dose- and route-dependent biokinetics. International Journal of Nanomedicine, 2018, Volume 13, 2631-2646.	3.3	29
83	Persistent aluminum accumulation after prolonged systemic aluminum exposure. Biological Trace Element Research, 1983, 5, 467-474.	1.9	27
84	The characterization of purified citrate-coated cerium oxide nanoparticles prepared via hydrothermal synthesis. Applied Surface Science, 2021, 535, 147681.	3.1	27
85	A safe method to acid digest small samples of biological tissues for graphite furnace atomic absorption analysis of aluminum. Biological Trace Element Research, 1983, 5, 225-237.	1.9	26
86	Brain microvascular endothelial cell association and distribution of a 5 nm ceria engineered nanomaterial. International Journal of Nanomedicine, 2012, 7, 4023.	3.3	26
87	Rat hippocampal responses up to 90 days after a single nanoceria dose extends a hierarchical oxidative stress model for nanoparticle toxicity. Nanotoxicology, 2014, 8, 155-166.	1.6	26
88	Persistent Hepatic Structural Alterations Following Nanoceria Vascular Infusion in the Rat. Toxicologic Pathology, 2014, 42, 984-996.	0.9	26
89	Aluminum transport out of brain extracellular fluid is proton dependent and inhibited by mersalyl acid, suggesting mediation by the monocarboxylate transporter (MCT1). Toxicology, 1998, 127, 59-67.	2.0	25
90	Methyl-Hydroxypyridinecarboxylic Acids as Possible Bidentate Chelating Agents for Aluminium(III): Synthesis and Metalâ€"Ligand Solution Chemistry. European Journal of Inorganic Chemistry, 2006, 2006, 1284-1293.	1.0	24

#	Article	IF	Citations
91	Physicochemical properties of engineered nanomaterials that influence their nervous system distribution and effects. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 2081-2093.	1.7	22
92	Reduced intestinal calcium and dietary calcium intake, increased aluminum absorption, and tissue concentration in the rat. Biological Trace Element Research, 1989, 23, 119-132.	1.9	21
93	Renal accumulation and urinary excretion of cisplatin in diabetic rats. Toxicology, 1991, 70, 151-162.	2.0	21
94	Selective adherence of a sucralfateâ€"tetracycline complex to gastric ulcers: Implications for the treatment ofHelicobacter pylori. Biopharmaceutics and Drug Disposition, 1995, 16, 475-479.	1.1	21
95	Hippocampal Acetylcholine Increases During Eyeblink Conditioning in the Rabbit. Physiology and Behavior, 1996, 60, 1199-1203.	1.0	21
96	Aluminum mobilization by desferrioxamine assessed by microdialysis of the blood, liver and brainâ˜†â˜†â˜†. Toxicology, 1991, 66, 313-324.	2.0	20
97	Delayed elevation of platelet activating factor in ischemic hippocampus. Brain Research, 1995, 691, 243-247.	1.1	20
98	1,6-Dimethyl-4-hydroxy-3-pyridinecarboxylic acid and 4-hydroxy-2-methyl-3-pyridinecarboxylic acid as new possible chelating agents for iron and aluminium. Dalton Transactions, 2009, , 1815.	1.6	20
99	Nanoceria biodistribution and retention in the rat after its intravenous administration are not greatly influenced by dosing schedule, dose, or particle shape. Environmental Science: Nano, 2014, 1, 549-560.	2.2	20
100	Carboxylic acids accelerate acidic environment-mediated nanoceria dissolution. Nanotoxicology, 2019, 13, 455-475.	1.6	19
101	Nanoparticle brain delivery: a guide to verification methods. Nanomedicine, 2020, 15, 409-432.	1.7	19
102	Aluminium Toxicokinetics: An Updated MiniReview. Basic and Clinical Pharmacology and Toxicology, 2001, 88, 159-167.	0.0	18
103	Tissue Specific Fate of Nanomaterials by Advanced Analytical Imaging Techniques - A Review. Chemical Research in Toxicology, 2020, 33, 1145-1162.	1.7	18
104	Simulated biological fluid exposure changes nanoceriaâ€™s surface properties but not its biological response. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 144, 252-265.	2.0	17
105	Extinction responding following amphetamine self-administration: Determination of reinforcement magnitude. Physiological Psychology, 1976, 4, 39-42.	0.8	16
106	The Pharmacokinetics and Toxicology of Aluminum in the Brain. Current Inorganic Chemistry, 2012, 2, 54-63.	0.2	16
107	Analytical High-resolution Electron Microscopy Reveals Organ-specific Nanoceria Bioprocessing. Toxicologic Pathology, 2018, 46, 47-61.	0.9	16
108	Aluminum chelation by 3-hydroxypyridin-4-ones in the rat demonstrated by microdialysis. Biological Trace Element Research, 1996, 53, 193-203.	1.9	15

#	Article	IF	Citations
109	Surface-controlled dissolution rates: a case study of nanoceria in carboxylic acid solutions. Environmental Science: Nano, 2019, 6, 1478-1492.	2.2	14
110	Direct nose to the brain nanomedicine delivery presents a formidable challenge. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022, 14, e1767.	3.3	14
111	Postmortem elevation in extracellular glutamate in the rat hippocampus when brain temperature is maintained at physiological levels: implications for the use of human brain autopsy tissues. Brain Research, 1999, 831, 104-112.	1.1	12
112	Assessing nanoparticle risk poses prodigious challenges. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2013, 5, 374-387.	3.3	12
113	Effect of Dietary Aluminum Sulfate on Calcium and Phosphorus Metabolism of Broiler Chicks. Poultry Science, 1990, 69, 985-991.	1.5	11
114	Pharmacokinetics of aluminum 3-hydroxypyridin-4-one complexes: implications for aluminum redistribution subsequent to chelation therapy. Toxicology, 1994, 92, 193-202.	2.0	11
115	Nanoceria distribution and effects are mouse-strain dependent. Nanotoxicology, 2020, 14, 827-846.	1.6	11
116	Manganese toxicokinetics at the blood-brain barrier. Research Report (health Effects Institute), 2004, , 7-58; discussion 59-73.	1.6	11
117	Relationship of Dietary Aluminum, Phosphorus, and Calcium to Phosphorus and Calcium Metabolism and Growth Performance of Broiler Chicks. Poultry Science, 1990, 69, 966-971.	1.5	10
118	Complexation of 3,4-hydroxypyridinecarboxylic acids with Iron(III). Inorganica Chimica Acta, 2004, 357, 3753-3758.	1.2	10
119	Evaluation of 4-hydroxy-6-methyl-3-pyridinecarboxylic acid and 2,6-dimethyl-4-hydroxy-3-pyridinecarboxylic acid as chelating agents for iron and aluminium. Inorganica Chimica Acta, 2011, 373, 179-186.	1.2	10
120	Aluminum and Alzheimer's Disease: Should We Worry?. Journal of Pharmacy Practice, 1988, 1, 118-127.	0.5	9
121	26Al-containing acidic and basic sodium aluminum phosphate preparation and use in studies of oral aluminum bioavailability from foods utilizing 26Al as an aluminum tracer. Nuclear Instruments & Methods in Physics Research B, 2005, 229, 471-478.	0.6	9
122	Evaluation of 1-methyl-3,4-hydroxypyridinecarboxylic acids as possible bidentate chelating agents for iron(III): Metalâ€“ligand solution chemistry. Polyhedron, 2007, 26, 3227-3232.	1.0	8
123	Morphometric characteristics and time to hatch as efficacious indicators for potential nanotoxicity assay in zebrafish. Environmental Toxicology and Chemistry, 2018, 37, 3063-3076.	2.2	8
124	A comparison of four toxicology resources in respect to rates of retrieval and time required. Journal of Pediatrics, 1978, 92, 145-148.	0.9	7
125	The influence of dietary calcium reduction on aluminum absorption and kinetics in the rabbit. Biological Trace Element Research, 1989, 23, 109-117.	1.9	7
126	Mucosal Injury and Î³-Irradiation Produce Persistent Gastric Ulcers in the Rabbit. Gastroenterology, 1991, 100, 1201-1205.	0.6	7

#	Article	IF	Citations
127	Imatinib mesylate effects on zebrafish reproductive success: Gonadal development, gamete quality, fertility, embryo-larvae viability and development, and related genes. Toxicology and Applied Pharmacology, 2019, 379, 114645.	1.3	7
128	Past, Present and Future of Drug Information Centers as Catalysts for the Utilization of Drug Therapy Information. Drug Information Journal, 1977, 11, 11-16.	0.5	6
129	Effects of plant ingestion in rats determined by the conditioned taste aversion procedure. Toxicon, 1981, 19, 223-232.	0.8	6
130	Acute toxicity of latex microspheres. Toxicology Letters, 1981, 9, 165-170.	0.4	6
131	Benefit Vs. Risk of Oral Aluminum Forms: Antacid and Phosphate Binding Vs. Absorption. Drug and Chemical Toxicology, 1989, 12, 277-286.	1.2	6
132	Application of electron energy loss spectroscopy and electron spectroscopic imaging to aluminum determination in biological tissue. Biological Trace Element Research, 1994, 40, 39-48.	1.9	6
133	Aluminum and the Blood-Brain Barrier. , 2001, , 233-260.		6
134	Drug Information Communication via Television. Drug Information Journal, 1976, 10, 132-137.	0.5	5
135	Applying accelerator mass spectrometry for low-level detection of complex engineered nanoparticles in biological media. Journal of Pharmaceutical and Biomedical Analysis, 2014, 97, 81-87.	1.4	5
136	Aluminum Exposure Produces Learning and Memory Deficits. , 1994, , 301-318.		5
137	HPLC Quantitation of a Very Hydrophilic 3-Hydroxypyridin-4-one Chelator Using a Simple Separation Procedure and the Baseline File Subtraction Method. Journal of Chromatographic Science, 1996, 34, 52-57.	0.7	4
138	Aluminum and Phthalates in Calcium Gluconate. Journal of Pediatric Gastroenterology and Nutrition, 2017, 64, 109-114.	0.9	4
139	Toxicity of Aluminum Exposure to the Neonatal and Immature Rabbit. Toxicological Sciences, 1987, 9, 795-806.	1.4	3
140	A phase I trial of 5-day continuous infusion cisplatin and interferon ?. Cancer Chemotherapy and Pharmacology, 1995, 37, 39-46.	1.1	3
141	Aluminum and phosphorus separation: application to preparation of target from brain tissue for 26Al determination by accelerator mass spectrometry. Nuclear Instruments & Methods in Physics Research B, 1999, 152, 129-134.	0.6	3
142	Glomerular lesions in male rabbits treated with aluminium lactate: with special reference to microaneurysm formation. Experimental and Toxicologic Pathology, 2000, 52, 139-143.	2.1	3
143	A Filtration System That Greatly Reduces Aluminum in Calcium Gluconate Injection, USP Used to Prepare Parenteral Nutrition Solutions. Journal of Pediatric Pharmacology and Therapeutics, 2014, 19, 189-195.	0.3	3
144	Cerium dioxide, a Jekyll and Hyde nanomaterial, can increase basal and decrease elevated inflammation and oxidative stress. Nanomedicine: Nanotechnology, Biology, and Medicine, 2022, 43, 102565.	1.7	3

#	Article	IF	Citations
145	Sodium and potassium levels in antacids. American Journal of Health-System Pharmacy, 1977, 34, 200-202.	0.5	2
146	The Influence of Human and Data Retrieval Resources on the Patterns of Use of Drug Information. Drug Information Journal, 1979, 13, 84-90.	0.5	2
147	The influence of neuroleptics on amphetamine metabolism in the rat and guinea-pig*. Journal of Pharmacy and Pharmacology, 2011, 30, 719-721.	1.2	2
148	Neurological System. , 2017, , 275-312.		2
149	Laser irradiation as a novel alternative to detach intact particulate matter collected on air filters. Chemosphere, 2022, 286, 131713.	4.2	2
150	Methods to Quantify Nanomaterial Association with, and Distribution Across, the Bloodâ€“Brain Barrier In Vivo. Methods in Molecular Biology, 2019, 1894, 281-299.	0.4	1
151	The effect of citrate, maltolate and fluoride on oral ²⁶ Al absorption. FASEB Journal, 2006, 20, A1141.	0.2	1
152	Toxic and Essential Trace Element Content of Commonly Administered Pediatric Oral Medications. Journal of Pediatric Pharmacology and Therapeutics, 2017, 22, 193-202.	0.3	1
153	The Impact of Video Technology on the Use of Drug Information Resources. Drug Information Journal, 1980, 14, 77-81.	0.5	0
154	Evaluation of Factors Influencing the Patterns of Use of Drug and Poison Information Resources. Drug Information Journal, 1982, 16, 216-226.	0.5	0
155	Puppet Show Illustrates Principles of Poison Prevention. American Journal of Health-System Pharmacy, 1983, 40, 1892-1892.	0.5	0
156	Introduction to the themed collection on nanoceria research. Environmental Science: Nano, 2014, 1, 514-515.	2.2	0
157	Correction to Some Statements about Aluminum in Sulaiman et al.. Chemical Research in Toxicology, 2021, 34, 935-935.	1.7	0
158	The preparation temperature influences the physicochemical nature and activity of nanoceria. Beilstein Journal of Nanotechnology, 2021, 12, 525-540.	1.5	0
159	Oral aluminum bioavailability from two representative foods is considerably less than from water. FASEB Journal, 2006, 20, A197.	0.2	0
160	Mucosal injury and Î³-irradiation produce persistent gastric ulcers in the rabbit. Gastroenterology, 1991, 100, 1201-1205.	0.6	0
161	Plasma and Serum Proteins Bound to Nanoceria: Insights into Pathways by which Nanoceria may Exert Its Beneficial and Deleterious Effects. Journal of Nanomedicine & Nanotechnology, 2020, 11, .	1.1	0
162	A phase I trial of 5-day continuous infusion cisplatin and interferon Î±. Cancer Chemotherapy and Pharmacology, 1995, 37, 39-46.	1.1	0